EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data

Jongsoo Lee iD, Miho Song, Subeen Leem iD, Jong-Yeup Kim, Benjamin I Chung, Sung Ryul Shim iD, Jae Heon Kim iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0335459 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Jongsoo Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Androgen Receptor Antagonists, Receptors, Androgen. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Soonchunhyang University Research Fund, National Research Foundation of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

While clinical RCTs have clearly evidenced that the use of androgen receptor pathway inhibitor (ARPI)s for patients with advanced prostate cancer, can significantly delay disease progression, there is insufficient evidence on their safety profiles to warrant their unqualified implementation as the treatment of choice or with which to choose between them. We aim to provide more substantial evidence for adverse event (AE)s of ARPI by analyzing real-world data (RWD) to select optimal ARPI for individual treatment. Materials and Methods We used data from the Food and Drug Administration Adverse Event Reporting System (FAERS) in the US, between April 30, 2014 and April 30, 2024.

Results

We estimated proportional risk ratio (PRR)s of AEs in the US. We also compared the likelihood of AEs by age, reporter type, and ARPI groups: 1) Group 1, Enzalutamide with other medications; 2) Group 2, Apalutamide with other medications; 3) Group 3, Darolutamide with other medications; 4) Group 4, Abiraterone with other medications; 5) Group 5, Abiraterone + Enzalutamide with other medications. We identified 107,582 AEs among 44,856 US residents who were treated with ARPIs for prostate cancer. By ARPI groups, the AE of GI was the highest in Group 1 and Group 3, and the AE of vascular was the highest in Group 4 and Group 5. In particular, Group 2 showed very statistically significantly higher levels of PRR 3.558 (95%CI: 3.489–3.627) of skin-related AE compared to other groups.

Conclusion

Our study provides important insight that we analyzed RWD and evaluated comparative drug safety across all type of prostate cancer. Although we could not make a conclusion whether which is the safest ARPI, we can suggest that each ARPIs have different types of AEs hence we can use this information during choosing ARPIs for prostate cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsAndrogen Receptor AntagonistsReceptors, AndrogenMaleHumansNitrilesAgedBenzamidesMiddle AgedPhenylthiohydantoinPyrazolesThiohydantoinsUnited StatesAdverse Drug Reaction Reporting SystemsAged, 80 and overUnited States Food and Drug AdministrationAndrostenes

Substanzen

Androgen Receptor AntagonistsNitrilesBenzamidesReceptors, AndrogenenzalutamidePhenylthiohydantoindarolutamidePyrazolesapalutamideThiohydantoins

Autor:innen und Institutionen

  • Department of Urology, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Department of Urology, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Republic of Korea.
  • Evidence Based Research Center, Konyang University Hospital, Daejeon, Republic of Korea.
  • Department of Biomedical Informatics, College of Medicine, Konyang University, Daejeon, Republic of Korea.
  • Department of Otorhinolaryngology-Head and Neck Surgery, College of Medicine, Konyang University, Daejeon, Republic of Korea.
  • Department of Urology, Stanford University Medical Center, Stanford, California, United States of America.

ORCID-Profile: Jongsoo Lee, Subeen Leem, Sung Ryul Shim, Jae Heon Kim

Förderung

  • Soonchunhyang University Research Fund
  • National Research Foundation of Korea

Zitieren

APA

Lee, J., Song, M., Leem, S., Kim, J. Y., Chung, B. I., Shim, S. R., & Kim, J. H. (2025). Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data. PLOS One. https://doi.org/10.1371/journal.pone.0335459

Vancouver

Lee J, Song M, Leem S, Kim JY, Chung BI, Shim SR, et al. Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data. PLOS One. 2025. doi:10.1371/journal.pone.0335459

BibTeX
@article{Lee2025,
  author = {Lee, Jongsoo and Song, Miho and Leem, Subeen and Kim, Jong-Yeup and Chung, Benjamin I and Shim, Sung Ryul and Kim, Jae Heon},
  title = {Adverse events of androgen receptor pathway inhibitors in prostate cancer from real world data},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0335459}
}
Kostenlos starten →